Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Iradimed (IRMD) over the last 12 years, with Q3 2025 value amounting to $2.4 million.

  • Iradimed's Long-Term Deferred Tax fell 170.91% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 170.91%. This contributed to the annual value of $2.8 million for FY2024, which is 3286.45% up from last year.
  • Per Iradimed's latest filing, its Long-Term Deferred Tax stood at $2.4 million for Q3 2025, which was down 170.91% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Long-Term Deferred Tax ranged from a high of $2.8 million in Q4 2024 and a low of $622206.0 during Q1 2023
  • In the last 5 years, Iradimed's Long-Term Deferred Tax had a median value of $1.8 million in 2023 and averaged $1.6 million.
  • As far as peak fluctuations go, Iradimed's Long-Term Deferred Tax crashed by 6015.46% in 2021, and later surged by 20288.43% in 2023.
  • Quarter analysis of 5 years shows Iradimed's Long-Term Deferred Tax stood at $765096.0 in 2021, then fell by 8.39% to $700867.0 in 2022, then soared by 202.88% to $2.1 million in 2023, then skyrocketed by 32.86% to $2.8 million in 2024, then dropped by 14.11% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.6 million for Q2 2025, and $2.7 million during Q1 2025.